US2022202701A1PendingUtilityA1

Compositions and methods to promote wound healing

Assignee: UNIV WAYNE STATEPriority: Mar 11, 2015Filed: Mar 15, 2022Published: Jun 30, 2022
Est. expiryMar 11, 2035(~8.6 yrs left)· nominal 20-yr term from priority
Inventors:Fu-Shin X. Yu
C07K 14/545A61L 2300/432A61K 9/0019A61P 27/02A61L 2300/436A61K 38/1858A61K 47/38A61K 47/02A61L 15/28A61P 17/02A61L 2300/426A61L 15/60A61L 2300/414A61L 26/008A61L 15/18A61L 2430/32A61L 15/44A61K 9/06A61K 38/1793A61P 25/00A61L 2430/34A61K 9/0014A61L 26/0066
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure describes compositions and methods to promote wound healing. The compositions and methods include an interleukin-1 beta (IL-1β) receptor antagonist (IL-1Ra), such as anakinra. The IL-1Ra can be administered topically to a chronic wound including a diabetic ulcer.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A topical composition comprising a therapeutic agent consisting of:
 a therapeutic protein consisting of the sequence provided in SEQ ID NO: 26 (anakinra); and   a platelet-derived growth factor (PDGF) or another growth factor, in a therapeutically effective amount.   
     
     
         2 . The topical composition of  claim 1 , wherein the composition is a gel, ointment, paste, lotion, powder, spray, or cream. 
     
     
         3 . The topical composition of  claim 1 , further comprising a thickening agent. 
     
     
         4 . The topical composition of  claim 3 , wherein the thickening agent is carboxymethylcellulose sodium. 
     
     
         5 . The topical composition of  claim 1 , further comprising a surfactant. 
     
     
         6 . The topical composition of  claim 5 , wherein the surfactant is a co-polymer having the formula 
       
         
           
           
               
               
           
         
       
       wherein x is 2 to 130, y is 15 to 70, and z is 2 to 130. 
     
     
         7 . The topical composition of  claim 1 , further comprising a buffer. 
     
     
         8 . The topical composition of  claim 7 , wherein the buffer comprises Phosphate Buffered Saline (PBS). 
     
     
         9 . The topical composition of  claim 1 , formulated as an additive to a wound dressing. 
     
     
         10 . The topical composition of  claim 9 , wherein the wound dressing comprises an adhesive bandage. 
     
     
         11 . The topical composition of  claim 1 , wherein the PDGF is Becaplermin (Regnarex™) 
     
     
         12 . The topical composition of  claim 1 , which is formulated to promote healing of a chronic wound in a diabetic subject. 
     
     
         13 . The tropical composition of  claim 1 , wherein the growth factor is a transforming growth factor (TGF).

Join the waitlist — get patent alerts

Track US2022202701A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.